Acute pancreatitis: Overview of medical aspects

Pancreas

Volumn 16, Issue 3, 1998, Pages 307-311

  Watanabe, Shin Ichioro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute pancreatitis; Antiprotease agents; Japan; Medical treatment

Indexed keywords

APROTININ; CHYMOTRYPSIN; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; GABEXATE MESILATE; KALLIKREIN; NAFAMSTAT MESILATE; PHOSPHOLIPASE A2; PLASMIN; PROTEINASE INHIBITOR; THROMBIN; TRYPSIN;

ACUTE PANCREATITIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; EDEMA; HEMOFILTRATION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; JAPAN; MAJOR CLINICAL STUDY; PANCREAS NECROSIS; PERITONEUM LAVAGE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0031892947     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199804000-00016     Document Type: Review

References (31)

1. Saitoh Y, ed. Severe acute pancreatitis in Japan-guidelines for diagnosis and treatment. Tokyo: Kokusai Tosho Shuppan, 1991.
2. Matsuno S. Guidelines for the treatment of severe acute pancreatitis. In: Matsuno S, éd. A report of the research committee for intractable diseases of the pancreas of the Department of Health and Welfare in 1996. Sendai: The Research Committee for Intractable Diseases of the Pancreas, First Department of Surgery, University of Tohoku, 1996:27-35.
3. Creutzfeldt W, Schmidt H. Aetiology and pathogenesis of pancreatitis. Scand J Gastroenterol 1970;6(suppl):67-62.
4. Trapnell JE, Rigby CG, Talbot CH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Siirg 1974;61:177-82.
5. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with Trasylol: report of a controlled therapeutic trial. Br Med J 1965;2:627-9.
6. Bachrach WH, Schild PD. A double-blind study of Trasylol in the treatment of pancreatitis. Ann NY Acad Sei 1968;146:580-90.
7. Cox AG. Death from acute pancreatitis. MRC multicenter trial of glucagon and aprotinin. Lancet 1977;22:632-5.
8. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. BrJSiirg 1978;65:337-41.
9. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, Clr and Cl esterase. Biochem Biophys Acta 1977;484:417-22.
10. Fujii S, Hitomi Y. New synthetic inhibitors of Clr, CI esterase, thrombin, plasmin, kallikrein and trypsin. Biochem Biophys Acta 1981 ;661:342-5.
11. Aoyama T, Ino Y, Ozaki M, et ai. Pharmacological studies of FUT-175, nafamostat mesilate. 1. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984;35:203-27.
12. Muramatsu M, Mon S, Matsuzawa Y, Horiguchi Y, Tanaka M. Purification and characterization of urinary trypsin inhibitor UTI68 from normal human urine and its cleavage by human uropepsin. J Biochem 1980;88:1317-29.
13. Ogawa M, Nishibe S, Mon T, Neumann S. Effect of human urinary trypsin inhibitor on granulocyte elastase activity. Res Commun Ghent Pathol Pharmacol 1987:55:271-4.
14. Ohshio G, Saluja AK, Leli U, Sengupta A, Steer ML. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. Gaslroenterology 1989;96:853-9.
15. Niederau C, Liddle RA, Ferrell LD, Grendell JH. Beneficial effects of cholecystokinin receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice: evidence for cholecystokinin as a major factor in the devel- | opment of acute pancreatitis. J Clin Invest 1986;78:1056-63.
16. Wisner JR Jr, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceraletide-induced acute pancreatitis in the rat. Pancreas 1987;2:181-<>.
17. Wisner JR Jr, Ozawa S, Renner G. The effects of nafamostat mesilate (FUT-175) on cerulein induced acute pancreatitis in the rat. Int J Pancreatol 1989;4:383-90.
18. Suzuki M, Isaji S, Stanten R, Frey CF, Ruebner B. Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. Int J Pancreatol 1992;11:59-65.
19. Ohnishi H, Kosuzume H, Ashida Y, Kalo K, Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sei 1984;29:26-32.
20. Preise J, Melzer P, Schmidt FW, Horbach L. Gabexat mesilat in der Behandlung der Akuten Pankreatitis. Ergebnisse der Hannoverschen Multizentrischen Deppelblindstudie mit 50 Patienten. Z Gastroenterol 1986;24:200-11.
21. Yang CY, Chang-chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987;2:698-700.
22. Pederzoli P, Cavallini G, Falconi M, et al. Gabexate mesilate vs aprotinin in human acute pancreatitis. Int J Pancreatol 1993;14: 117-24.
23. Harada H, Miyake H, Ochi K, et al. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991;9:75-9.
24. Takeuchi T, Takebe T, Sato T, et al. Clinical evaluation of f UT175 (nafamostat mesilate) on pancreatitis. A double-blind con- .s' trolled study with gabexate mesilate. Digest Med 1984; 1:255-70. -
25. Yamamura H, Tamakuma S, Nakashima M. Clinical evaluation of MR-20 on shock. A double-blind controlled study with aprotinin. J Clin Exp Med 1984;129:730-8.
26. Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993:104:1165-70.
27. Kuno N, Kasugai T, Oguri T, et al. Study on prevention of complications associated with endoscopie retrograde cholangiopancreatography (ERCP): a controlled trial of a new protease inhibitor, Foy, in hyperamylasemia following endoscopie retrograde cholangiopancreatography. Gendai Iryo 1978; 10:571-7.
28. Inada Y, Yamada M, Kadohara M, et al. The clinical study on the effect of Foy on complications following endoscopie retrograde cholangiopancreatography. Gendai Iryo 1980;12:1493-7.
29. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopie retrograde cholangiopancreatography. N Engt J Med 1996:335:919-23.
30. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996;171:394-8.
31. Ranson JHC, Berman RS. Long peritoneal lavage decreased pancreatic sepsis in acute pancreatitis. Ann Surg 1990;211:708-16.